International Journal of Endocrinology and Metabolism

Published by: Kowsar

Tehran Lipid and Glucose Study: A National Legacy

Fereidoun Azizi 1 , *
Author Information
1 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Endocrinology and Metabolism: October 2018, 16 (4 (Suppl)); e84774
  • Published Online: October 9, 2018
  • Article Type: Editorial
  • Received: September 30, 2018
  • Accepted: October 6, 2018
  • DOI: 10.5812/ijem.84774

To Cite: Azizi F. Tehran Lipid and Glucose Study: A National Legacy, Int J Endocrinol Metab. 2018 ; 16(4 (Suppl)):e84774. doi: 10.5812/ijem.84774.

Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
References
  • 1. Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr. 2002;5(1A):149-55. doi: 10.1079/PHN2001287. [PubMed: 12027278].
  • 2. Sarrafzadegan N, Najafian J. Priorities in cardiovascular prevention in Iran. Iran Heart J. 1998;1(1):131.
  • 3. Azizi F, Gouya MM, Vazirian P, Dolatshahi P, Habibian S. The diabetes prevention and control programme of the Islamic Republic of Iran. East Mediterr Health J. 2003;9(5-6):1114-21. doi: 10.1007/s000380200008. [PubMed: 16450545].
  • 4. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed. 2002;47(6):408-26. [PubMed: 12643001].
  • 5. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5. doi: 10.1186/1745-6215-10-5. [PubMed: 19166627]. [PubMed Central: PMC2656492].
  • 6. Azizi F. Tehran lipid and glucose study: A legacy for prospective community-based research. Arch Iran Med. 2014;17(6):392-3. [PubMed: 24916522].
  • 7. Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, et al. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am J Prev Med. 2010;38(6):628-636 e1. doi: 10.1016/j.amepre.2010.03.003. [PubMed: 20494239].
  • 8. Azizi F, Mirmiran P, Momenan AA, Hadaegh F, Habibi Moeini A, Hosseini F, et al. The effect of community-based education for lifestyle intervention on the prevalence of metabolic syndrome and its components: tehran lipid and glucose study. Int J Endocrinol Metab. 2013;11(3):145-53. doi: 10.5812/ijem.5443. [PubMed: 24348586]. [PubMed Central: PMC3860109].
  • 9. Wong ND, Levy D. Legacy of the framingham heart study: Rationale, design, initial findings, and implications. Glob Heart. 2013;8(1):3-9. doi: 10.1016/j.gheart.2012.12.001. [PubMed: 25690260].
  • 10. Mirbolouk M, Derakhshan A, Charkhchi P, Guity K, Azizi F, Hadaegh F. Incidence and predictors of early adulthood pre-diabetes/type 2 diabetes, among Iranian adolescents: The Tehran Lipid and Glucose Study. Pediatr Diabetes. 2016;17(8):608-16. doi: 10.1111/pedi.12343. [PubMed: 26764014].
  • 11. Daneshpour MS, Fallah MS, Sedaghati-Khayat B, Guity K, Khalili D, Hedayati M, et al. Rationale and design of a genetic study on cardiometabolic risk factors: Protocol for the Tehran Cardiometabolic Genetic Study (TCGS). JMIR Res Protoc. 2017;6(2). e28. doi: 10.2196/resprot.6050. [PubMed: 28232301]. [PubMed Central: PMC5344981].
  • 12. Azizi F. Precision medicine for endocrinology. Int J Endocrinol Metab. 2016;14(3). e40283. doi: 10.5812/ijem.40283. [PubMed: 28115967]. [PubMed Central: PMC5219894].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments